source
- Medicare falls short on projected Alzheimer’s drug costs as fewer seniors use LeqembiBob Herman reports that Medicare's earlier estimate that the new Alzheimer's therapy Leqembi would cost the program $3.5 billion in 2025 has proved far too high. The agency's actuaries based the fo…
- FDA policy lets some flavored vapes stay on shelves without full approval, raising expert concernsThe Food and Drug Administration announced a new guidance that allows certain flavored e-cigarettes and nicotine pouches to remain on the market even though they have not received full authorizatio…